Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Protalix’s mission is to develop transformative plant-based biologics for severe, pervasive and neglected rare diseases, offering patients and their families improved quality of life and hope for the future.

Protalix’s vision is to be a recognized leader in transforming plant-based biologics into innovative and meaningful therapies that address the unmet needs of patients suffering from rare and neglected diseases.

The Company has received numerous awards, including the European Rare and Orphan Drug Designation for Elelyso™, the Italian Orphan Drug Designation for OPDIVO™, the U.S. Orphan Drug Designation for OPDIVO™, and the U.S. Rare Pediatric Disease Designation for Elemente™.